{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:27:14Z","timestamp":1792124834730,"version":"4.4.0"},"reference-count":35,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T00:00:00Z","timestamp":1660089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Objective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test (SNOT)-22 score, Nasal Polyp (NP) score, and blood eosinophil count during a 12-month treatment with mepolizumab. Secondary endpoints were to quantify mepolizumab\u2019s effects on the mentioned parameters, identify clinical variables influencing the degree of response to treatment, and portray responder and nonresponder patients. Methods: A multicentric retrospective no-profit observational study on severe asthmatic patients, treated with mepolizumab, and comorbid CRSwNP was conducted. All patients were followed for at least 12 months. SNOT-22 score, NP score, and blood eosinophil count (and other CRS-specific variables) were collected at baseline and after 12 months. Results: Forty-three patients were included. A statistically significant reduction was observed for SNOT-22 score (mean t0 SNOT-22 54.8 \u00b1 25.9; mean t12 SNOT-22 31.5 \u00b1 21.3, p &lt; 0.0001), NP score (median t0 NPS 3 (IQR 3); median t12 NPS 2 (IQR 4), p &lt; 0.0001), and blood eosinophil count (mean t0 blood eosinophils 804.7 \u00b1 461.5 cell\/\u00b5L; mean t12 blood eosinophils 107.5 \u00b1 104.6 cell\/\u00b5L, p &lt; 0.0001) after 12 months of treatment. Twenty patients (47%) gained improvement both in clinical and endoscopic outcome. Mepolizumab responder patients presented a t0 SNOT-22 significantly higher than nonresponders (p = 0.0011). Conclusions: Mepolizumab improved CRSwNP outcomes in a population of severe asthmatic patients. No clinical feature emerged to outline the profile of a \u201ctypical\u201d responder patient, except for baseline SNOT-22 score, which seemed to affect the response to treatment. Further studies would be necessary to supplement these preliminary evaluations.<\/jats:p>","DOI":"10.3390\/jpm12081304","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T09:46:24Z","timestamp":1660124784000},"page":"1304","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study"],"prefix":"10.3390","volume":"12","author":[{"given":"Stefania","family":"Gallo","sequence":"first","affiliation":[{"name":"Department of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, Italy"},{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Castelnuovo","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, Italy"},{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Spirito","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, Italy"},{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Feduzi","sequence":"additional","affiliation":[{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6297-8034","authenticated-orcid":false,"given":"Veronica","family":"Seccia","sequence":"additional","affiliation":[{"name":"Otolaryngology Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Visca","sequence":"additional","affiliation":[{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"},{"name":"Division of Pulmunary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, 21049 Tradate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Spanevello","sequence":"additional","affiliation":[{"name":"UPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, Italy"},{"name":"Division of Pulmunary Rehabilitation, Istituti Clinici Scientifici Maugeri, IRCCS, 21049 Tradate, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Statuti","sequence":"additional","affiliation":[{"name":"Otolaryngology Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56124 Pisa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Latorre","sequence":"additional","affiliation":[{"name":"Department of Medical Specialties, Pulmonary Unit, Hospital of Massa, 54100 Massa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2070-0314","authenticated-orcid":false,"given":"Claudio","family":"Montuori","sequence":"additional","affiliation":[{"name":"Department of Head and Neck and Sensory Organs, Catholic University of the Sacred Heart, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6795-746X","authenticated-orcid":false,"given":"Angela","family":"Rizzi","sequence":"additional","affiliation":[{"name":"Unit of Allergology, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Boccabella","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Geriatrics, Catholic University of the Sacred Hearth, 00168 Rome, Italy"},{"name":"Unit of Pulmonology, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bonini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Geriatrics, Catholic University of the Sacred Hearth, 00168 Rome, Italy"},{"name":"Unit of Pulmonology, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5761-7018","authenticated-orcid":false,"given":"Eugenio","family":"De Corso","sequence":"additional","affiliation":[{"name":"Department of Head and Neck and Sensory Organs, Catholic University of the Sacred Heart, 00168 Rome, Italy"},{"name":"Unit of Otorhinolaryngology, A. Gemelli University Hospital Foundation IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/DDDT.S150656","article-title":"Severe eosinophilic asthma: From the patho-genic role of interleukin-5 to the therapeutic action of mepolizumab","volume":"11","author":"Pelaia","year":"2017","journal-title":"Drug. Des. Devel. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","article-title":"The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronica rhinosinusitis","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"ref_3","unstructured":"(2022, June 30). 2020 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2020\/04\/GINA-2020-full-report_-final-_wms.pdf."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.jaip.2020.01.009","article-title":"Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps","volume":"8","author":"Chan","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Detoraki, A., Tremante, E., D\u2019Amato, M., Calabrese, C., Casella, C., Maniscalco, M., Poto, R., Brancaccio, R., Boccia, M., and Martino, M. (2021). Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: A 12-month real-life study. Ther. Adv. Respir. Dis., 15.","DOI":"10.1177\/17534666211009398"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and iden-tification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.jaci.2020.02.002","article-title":"Severe eosinophilic asthma with nasal polyposis: A phenotype for improved sinonasal and asthma outcomes with mepolizumab therapy","volume":"145","author":"Howarth","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_9","first-page":"100791","article-title":"Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis","volume":"78","author":"Sposato","year":"2020","journal-title":"Respir. Med. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jaci.2020.05.054","article-title":"Eosinophil paradox with mepolizumab in chronic rhinosinusitis with nasal polyposis","volume":"146","author":"Lipworth","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.14639\/0392-100X-N0716","article-title":"Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients","volume":"40","author":"Bandi","year":"2020","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_12","unstructured":"(2022, June 30). 2017 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/04\/wmsGINA-2017-main-report-final_V2.pdf."},{"key":"ref_13","unstructured":"(2022, June 30). 2018 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/01\/2018-GINA.pdf."},{"key":"ref_14","unstructured":"(2022, June 30). 2019 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2019\/06\/GINA-2019-main-report-June-2019-wms.pdf."},{"key":"ref_15","unstructured":"(2022, June 30). 2021 GINA Report, Global Strategy for Asthma Management and Prevention. Available online: https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA-Main-Report-2021-V2-WMS.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.14639\/0392-100X-N0364","article-title":"Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis","volume":"40","author":"Gallo","year":"2020","journal-title":"Acta Otorhinolaryngol. Ital."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"105947","DOI":"10.1016\/j.rmed.2020.105947","article-title":"Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry","volume":"166","author":"Canonica","year":"2020","journal-title":"Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/alr.22064","article-title":"Asthma onset pattern and patient outcomes in a chronic rhinosinusitis popu-lation","volume":"8","author":"Price","year":"2018","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.13496","article-title":"Precision medicine in united airways disease: A \u201ctreatable traits\u201d approach","volume":"73","author":"Yii","year":"2018","journal-title":"Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S2213-2600(19)30372-8","article-title":"Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid- dependent asthma: Results from two phase 3, randomised, double-blind, placebo-controlled trials","volume":"8","author":"Bernstein","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12016-021-08844-7","article-title":"Eosinophils in the Field of Nasal Poly-posis: Towards a Better Understanding of Biologic Therapies","volume":"62","author":"Vanderhaegen","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1146\/annurev-pathol-052016-100401","article-title":"Immunopathogenesis of Chronic Rhinosinusitis and Nasal Polyposis","volume":"12","author":"Schleimer","year":"2017","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jaci.2020.01.027","article-title":"Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin","volume":"145","author":"Takabayashi","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/alr.22214","article-title":"Highlights of eosinophilic chronic rhinosinusitis with nasal polyps in definition, prognosis, and advancement","volume":"8","author":"Lou","year":"2018","journal-title":"Int. Forum. Allergy Rhinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3906\/sag-1912-62","article-title":"Efficacy of mepolizumab treatment in oral corticoster-oid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: Single center, real life study","volume":"50","author":"Yilmaz","year":"2020","journal-title":"Turk. J. Med. Sci."},{"key":"ref_29","first-page":"PA3727","article-title":"Mepolizumab in the treatment of severe asthma with nasal polyposis: Real-life study","volume":"58","author":"Tinoco","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1159\/000514262","article-title":"Real-Life Experience of Monoclonal Antibody Treatments in Chronic Rhinosinusitis with Nasal Polyposis","volume":"182","author":"Meier","year":"2021","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tiotiu, A., Mendez-Brea, P., Ioan, I., Romero-Fernandez, R., Oster, J.P., Hoang, T.-C., Roux, P., Ochoa-Gutierrez, D.C., Bonniaud, P., and de Blay, F. (2022). Real-Life Effectiveness of Benralizumab, Mepolizumab and Omalizumab in Severe Allergic Asthma Associated with Nasal Polyps. Clin. Rev. Allergy Immunol., 1\u201314.","DOI":"10.1183\/13993003.congress-2022.758"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.jaip.2021.07.023","article-title":"The Choice of Biologics in Patients with Severe Chronic Rhinosinusitis with Nasal Polyps","volume":"9","author":"Lipworth","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"ref_33","first-page":"31","article-title":"Surgical versus medical treatment of nasal polyps","volume":"8","author":"Lildholdt","year":"1989","journal-title":"Rhinol. Suppl."},{"key":"ref_34","first-page":"E61","article-title":"Dexpramipexole depletes blood and tissue eosinophils in nasal polyps with no change in polyp size","volume":"129","author":"Laidlaw","year":"2018","journal-title":"Laryngoscope"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1002\/lary.25108","article-title":"Using preoperative SNOT-22 score to inform patient decision for Endoscopic sinus surgery","volume":"125","author":"Rudmik","year":"2014","journal-title":"Laryngoscope"}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/8\/1304\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:06:52Z","timestamp":1760141212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/12\/8\/1304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,10]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jpm12081304"],"URL":"https:\/\/doi.org\/10.3390\/jpm12081304","relation":{},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,10]]}}}